Abbott Laboratories Q3 2024 Adj. EPS $1.21 Beats $1.20 Estimate, Sales $10.635B Beat $10.549B Estimate
Portfolio Pulse from Benzinga Newsdesk
Abbott Laboratories reported its Q3 2024 financial results, with adjusted EPS of $1.21, surpassing the estimate of $1.20. The company's sales reached $10.635 billion, exceeding the expected $10.549 billion.
October 16, 2024 | 11:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Abbott Laboratories' Q3 2024 earnings report shows a slight beat on both EPS and sales estimates, indicating a positive performance.
Abbott Laboratories exceeded both EPS and sales estimates for Q3 2024, which is typically viewed positively by investors. This performance suggests operational strength and could lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100